Grey Matter Neurosciences
Developing non-invasive ultrasound technology to treat age-related brain diseases like Alzheimer's.
About
Grey Matter Neurosciences is a Toronto-based medical technology company focused on developing revolutionary, non-invasive neuromodulation products. Their core technology utilizes transcranial focused ultrasound to treat age-related brain diseases, aiming to empower seniors to manage cognitive and mood disorders outside of clinical settings.
Similar companies
Developing a novel therapeutic approach for Alzheimer's disease.
Shares Biotechnology, Medical Devices
Developing ultra-high bandwidth brain-machine interfaces to connect humans and computers.
Shares Neurotechnology, Medical Devices
A neurotechnology company developing implantable Brain-Computer Interfaces.
Shares Neurotechnology, Biotechnology
Developing a cortical visual prosthesis to restore functional vision for the severely blind.
Shares Neurotechnology, Medical Devices
NeuroTech company developing therapies to restore movement and independence for people with spinal cord injuries.
Shares Biotechnology, Medical Devices
Developing soft, stretchable brain-computer interface platforms.
Shares Biotechnology, Medical Devices
Key facts
- Headquarters
- Toronto, Canada
- Founded
- 2021
- Total funding
- $14M (Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 23 Jan 2025 | Seed | $14M |
Frequently asked
How much funding has Grey Matter Neurosciences raised?
Grey Matter Neurosciences has raised a total of $14M in funding. The most recent round on record is Seed.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Grey Matter Neurosciences
